Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)
3 Downloads (Pure)
Original languageUndefined/Unknown
Article numbere026779
JournalBMJ Open
Volume9
Issue number5
DOIs
Publication statusPublished - 2019

Cite this